Phase 2Completed
Vitamin K2 Intervention in Patients With Vitamin K Antagonists (SAFEK)
Study of the Effect of Food Vitamin K2 Intake in Association With a Fermented Dairy Product on Patients Treated With Vitamin K Antagonist (VKA)
- Sponsor
- Danisco (Industry)
- Enrollment
- 50 enrolled
- Conditions
- Thrombosis
- Interventions
- Vitamin K2
- Ages
- adults, older adults
- Registry
- NCT01533441
Full record on ClinicalTrials.gov
From the registry
The objective of the SAFE K study is to demonstrate that in patients treated with the antagonists of vitamin K (VKA), a daily intake of vitamin K2 (75 micrograms/day) as naturally produced by the ferments used in fermented dairy products, does not upset the balance of anticoagulant treatment.Fifty-two patients will be chosen to receive either verum or placebo for four months after a 4-month run-in period.In addition, the study evaluates if regular consumption of vitamin K2 reduce the need of changing the dose of anticoagulation treatment and improve the markers of bone mineralisation.
Primary outcomes
- INR
History
Last registry update
Primary completion
Registered
Started